7 DRUG INTERACTIONS
Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.
| Strong CP3A4 Inhibitors (e.g., ketoconazole) | |
| Clinical Impact | Increased exposure to tofacitinib |
| Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)] |
| Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole) | |
| Clinical Impact | Increased exposure to tofacitinib |
| Intervention | Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)] |
| Strong CYP3A4 Inducers (e.g., rifampin) | |
| Clinical Impact | Decreased exposure to tofacitinib and may result in loss of or reduced clinical response |
| Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended [see Clinical Pharmacology, Figure 3 (12.3)] |
| Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine) | |
| Clinical Impact | Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA. |
| Intervention | Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended [see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)] |